Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Braveheart aims for freedom with IPO to support Hengrui-licensed cardio asset

Braveheart aims for freedom with IPO to support Hengrui-licensed cardio asset

  • July 15, 2026

It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.

Leave A Comment

Fields (*) Mark are Required